Swedencare AB (publ) (SECARE.ST)
SEK 48.8
(-2.4%)
SEK 48.8
(-2.4%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 173.2 Million SEK | 37.37% |
| 2022 | 119.97 Million SEK | 85.84% |
| 2021 | 64.55 Million SEK | 6.94% |
| 2020 | 60.36 Million SEK | 63.53% |
| 2019 | 36.91 Million SEK | 25.44% |
| 2018 | 29.42 Million SEK | 76.16% |
| 2017 | 16.7 Million SEK | 47.49% |
| 2016 | 11.32 Million SEK | -7.2% |
| 2015 | 12.2 Million SEK | 96.95% |
| 2014 | 6.19 Million SEK | 512.71% |
| 2013 | -1.5 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 59.4 Million SEK | 10.61% |
| 2024 Q1 | 53.7 Million SEK | -2.36% |
| 2024 Q3 | 54.4 Million SEK | -8.42% |
| 2023 Q1 | 30.3 Million SEK | -14.1% |
| 2023 FY | 164.8 Million SEK | 37.37% |
| 2023 Q2 | 30.9 Million SEK | 1.98% |
| 2023 Q3 | 56.7 Million SEK | 83.5% |
| 2023 Q4 | 55 Million SEK | -3.0% |
| 2022 Q1 | 7.4 Million SEK | 112.82% |
| 2022 FY | 119.97 Million SEK | 85.84% |
| 2022 Q3 | 21.64 Million SEK | -43.41% |
| 2022 Q4 | 35.27 Million SEK | 63.01% |
| 2022 Q2 | 38.24 Million SEK | 416.52% |
| 2021 Q2 | 44.5 Million SEK | 31.35% |
| 2021 Q3 | 35.75 Million SEK | -19.66% |
| 2021 Q4 | -57.77 Million SEK | -261.59% |
| 2021 Q1 | 33.88 Million SEK | 39.19% |
| 2021 FY | 64.55 Million SEK | 6.94% |
| 2020 Q3 | 19.5 Million SEK | 195.95% |
| 2020 Q2 | 6.59 Million SEK | -38.48% |
| 2020 FY | 60.36 Million SEK | 63.53% |
| 2020 Q4 | 24.34 Million SEK | 24.78% |
| 2020 Q1 | 10.71 Million SEK | 77.15% |
| 2019 Q3 | 10.99 Million SEK | 27.01% |
| 2019 Q2 | 8.65 Million SEK | -18.93% |
| 2019 Q1 | 10.67 Million SEK | 45.65% |
| 2019 FY | 36.91 Million SEK | 25.44% |
| 2019 Q4 | 6.04 Million SEK | -44.99% |
| 2018 Q1 | 6.01 Million SEK | 12.71% |
| 2018 Q3 | 8.66 Million SEK | 16.77% |
| 2018 Q4 | 7.33 Million SEK | -15.37% |
| 2018 FY | 29.42 Million SEK | 76.16% |
| 2018 Q2 | 7.42 Million SEK | 23.42% |
| 2017 Q3 | 4.26 Million SEK | 214.39% |
| 2017 Q4 | 5.33 Million SEK | 25.21% |
| 2017 FY | 16.7 Million SEK | 47.49% |
| 2017 Q1 | 5.75 Million SEK | 1235.16% |
| 2017 Q2 | 1.35 Million SEK | -76.46% |
| 2016 Q1 | 4.33 Million SEK | 32.51% |
| 2016 Q4 | 431.18 Thousand SEK | -89.86% |
| 2016 Q3 | 4.25 Million SEK | 84.32% |
| 2016 Q2 | 2.3 Million SEK | -46.73% |
| 2016 FY | 11.32 Million SEK | -7.2% |
| 2015 Q1 | 2.31 Million SEK | 0.0% |
| 2015 FY | 12.2 Million SEK | 96.95% |
| 2015 Q4 | 3.27 Million SEK | 9.88% |
| 2015 Q2 | 3.64 Million SEK | 56.96% |
| 2015 Q3 | 2.97 Million SEK | -18.24% |
| 2014 FY | 6.19 Million SEK | 512.71% |
| 2013 FY | -1.5 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AcuCort AB | -13.24 Million SEK | 1407.268% |
| AlzeCure Pharma AB (publ) | -38.26 Million SEK | 552.668% |
| BioGaia AB (publ) | 440.9 Million SEK | 60.718% |
| Enzymatica AB (publ) | -48.06 Million SEK | 460.368% |
| Enorama Pharma AB (publ) | -41.83 Million SEK | 513.978% |
| Gabather AB (publ) | -9.47 Million SEK | 1928.161% |
| Klaria Pharma Holding AB (publ.) | -14.68 Million SEK | 1279.837% |
| Moberg Pharma AB (publ) | -27.46 Million SEK | 730.667% |
| Nanexa AB (publ) | -76.62 Million SEK | 326.036% |
| Newbury Pharmaceuticals AB (publ) | -14.07 Million SEK | 1330.288% |
| ODI Pharma AB | -1.34 Million SEK | 13009.573% |
| Orexo AB (publ) | -109.5 Million SEK | 258.174% |
| Probi AB (publ) | 11.32 Million SEK | -1430.035% |
| Swedish Orphan Biovitrum AB (publ) | 4.65 Billion SEK | 96.28% |
| Toleranzia AB | -7.89 Million SEK | 2294.906% |
| Vivesto AB | -356.71 Million SEK | 148.554% |